EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Critical Role of microRNA-33a/b in Cardiovascular and Metabolic Disease: Molecular Mechanisms and Therapeutic Perspectives

Takahiro Horie, Osamu Baba, Tomohiro Nishino, Yugo Yamashita, Yuta Tsujisaka, Koh Ono

Journal of Atherosclerosis and Thrombosis · 01.01.2026 · 33 (1) · 13-19

DOI: 10.5551/jat.rv22045 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Atherosclerosis and Thrombosis, erschienen am 01.01.2026. Verfasst von Takahiro Horie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University. Hauptthemen laut MEDLINE: MicroRNAs, Metabolic Diseases, Cardiovascular Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

MicroRNAs (miRNAs) serve as fundamental post-transcriptional regulators of gene expression, among which the miR-33 family, consisting of miR-33a and miR-33b, has emerged as a critical modulator in the pathogenesis of cardiovascular and metabolic diseases. These miRNAs are embedded within the intronic regions of SREBF genes and play pivotal roles in cholesterol homeostasis, fatty acid metabolism, and inflammatory regulation. Notably, miR-33a is highly conserved across various species, whereas miR-33b is found primarily in primates and some other mammals, complicating the development of relevant animal models. These miRNAs inhibit their target genes involved in cholesterol metabolism, fatty acid oxidation, and insulin signaling, consequently influencing the development and progression of cardiovascular and metabolic diseases. Inhibition or genetic ablation of miR-33 has shown therapeutic potential, improving dyslipidemia, atherosclerosis, and metabolic dysfunction-associated steatotic liver disease, through altered cholesterol metabolism, attenuation of inflammation, and increased fatty acid utilization. In addition, miR-33 suppression has been shown to promote skeletal muscle regeneration. However, systemic inhibition of miR-33 requires caution due to the role of miR-33 in hunger signaling and sympathetic nerve activity in the central nervous system, which may lead to obesity. Therefore, the development of tissue-specific strategies is essential for the safe and effective therapeutic targeting of miR-33.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsMetabolic DiseasesCardiovascular DiseasesHumansAnimals

Stichwörter der Autor:innen

Antisense oligonucleotideCardiovascular and metabolic diseaseMicroRNA-33aMicroRNA-33b

Substanzen

MicroRNAsMIRN33a microRNA, human

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University.

Zitieren

APA

Horie, T., Baba, O., Nishino, T., Yamashita, Y., Tsujisaka, Y., & Ono, K. (2026). Critical Role of microRNA-33a/b in Cardiovascular and Metabolic Disease: Molecular Mechanisms and Therapeutic Perspectives. Journal of Atherosclerosis and Thrombosis, 33(1), 13-19. https://doi.org/10.5551/jat.rv22045

Vancouver

Horie T, Baba O, Nishino T, Yamashita Y, Tsujisaka Y, Ono K. Critical Role of microRNA-33a/b in Cardiovascular and Metabolic Disease: Molecular Mechanisms and Therapeutic Perspectives. Journal of Atherosclerosis and Thrombosis. 2026;33(1):13-19. doi:10.5551/jat.rv22045

BibTeX
@article{Horie2026,
  author = {Horie, Takahiro and Baba, Osamu and Nishino, Tomohiro and Yamashita, Yugo and Tsujisaka, Yuta and Ono, Koh},
  title = {Critical Role of microRNA-33a/b in Cardiovascular and Metabolic Disease: Molecular Mechanisms and Therapeutic Perspectives},
  journal = {Journal of Atherosclerosis and Thrombosis},
  year = {2026},
  volume = {33},
  number = {1},
  pages = {13--19},
  doi = {10.5551/jat.rv22045}
}
Kostenlos starten →